AOS to face competition
Wednesday, 25 June, 2008
Advanced Ocular Systems (ASX: AOS) will have to contend with a new competitor for its Triesence injectable triamcinolone acetonide anti-inflammatory, company directors warned the market yesterday.
The new product, known as Trivaris, is manufactured by Allergan. The FDA recently approved the drug for sale.
It will be in direct competition with Triesence, which was developed by AOS and is sold under license through Alcon.
The potential effect on the company's royalties revenues is currently unclear, AOS said.
Injectable triamcinolone acetonide is mainly used to treat inflammation of the eyes and other similar ocular diseases and disorders.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
